Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients

Author： Kawano Kouichiro   Tsuda Naotake   Matsueda Satoko   Sasada Tetsuro   Watanabe Noriko   Ushijima Kimio   Yamaguchi Tomohiko   Yokomine Masato   Itoh Kyogo   Yamada Akira   Kamura Toshiharu  

Publisher： Informa Healthcare

ISSN： 0892-3973

Source： Immunopharmacology and Immunotoxicology, Vol.36, Iss.3, 2014-06, pp. : 224-236

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study

By Morgan Robert  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 723-728

Springer Publishing Company

Access to resources Recommend Favorite

Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13)

By Harter Philipp   Sehouli Jalid   Kimmig Rainer   Rau Jörn   Hilpert Felix   Kurzeder Christian   Elser Gabriele   Bois Andreas  

Investigational New Drugs, Vol. 31, Iss. 6, 2013-12 ,pp. : 1499-1504

Springer Publishing Company

Access to resources Recommend Favorite

Personalized Peptide Vaccine for Treatment of Advanced Cancer

By  

Current Medicinal Chemistry, Vol. 21, Iss. 21, 2014-07 ,pp. : 2332-2345

Bentham Science Publishers

Access to resources Recommend Favorite

Cancer vaccination with telomerase peptide GV1001

By Kyte Jon Amund  

Expert Opinion on Investigational Drugs, Vol. 18, Iss. 5, 2009-05 ,pp. : 687-694

Informa Healthcare

Access to resources Recommend Favorite

CTL precursor-oriented peptide vaccination in colorectal cancer

By  

Inpharma, Vol. 1, Iss. 1440, 2004-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite